![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BTG2 |
Gene summary for BTG2 |
![]() |
Gene information | Species | Human | Gene symbol | BTG2 | Gene ID | 7832 |
Gene name | BTG anti-proliferation factor 2 | |
Gene Alias | APRO1 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P78543 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7832 | BTG2 | P8T-E | Human | Esophagus | ESCC | 5.20e-39 | 1.65e+00 | 0.0889 |
7832 | BTG2 | P9T-E | Human | Esophagus | ESCC | 3.86e-27 | 1.52e+00 | 0.1131 |
7832 | BTG2 | P10T-E | Human | Esophagus | ESCC | 4.42e-16 | 1.06e+00 | 0.116 |
7832 | BTG2 | P11T-E | Human | Esophagus | ESCC | 1.18e-32 | 2.80e+00 | 0.1426 |
7832 | BTG2 | P12T-E | Human | Esophagus | ESCC | 1.54e-28 | 1.40e+00 | 0.1122 |
7832 | BTG2 | P15T-E | Human | Esophagus | ESCC | 1.10e-30 | 1.59e+00 | 0.1149 |
7832 | BTG2 | P16T-E | Human | Esophagus | ESCC | 2.11e-39 | 1.60e+00 | 0.1153 |
7832 | BTG2 | P17T-E | Human | Esophagus | ESCC | 7.65e-04 | 1.39e+00 | 0.1278 |
7832 | BTG2 | P19T-E | Human | Esophagus | ESCC | 1.53e-05 | 1.53e+00 | 0.1662 |
7832 | BTG2 | P20T-E | Human | Esophagus | ESCC | 3.32e-32 | 2.92e+00 | 0.1124 |
7832 | BTG2 | P21T-E | Human | Esophagus | ESCC | 5.74e-35 | 1.62e+00 | 0.1617 |
7832 | BTG2 | P22T-E | Human | Esophagus | ESCC | 1.28e-38 | 1.33e+00 | 0.1236 |
7832 | BTG2 | P23T-E | Human | Esophagus | ESCC | 1.51e-44 | 3.77e+00 | 0.108 |
7832 | BTG2 | P24T-E | Human | Esophagus | ESCC | 4.32e-14 | 1.44e+00 | 0.1287 |
7832 | BTG2 | P26T-E | Human | Esophagus | ESCC | 1.69e-73 | 2.71e+00 | 0.1276 |
7832 | BTG2 | P27T-E | Human | Esophagus | ESCC | 5.15e-78 | 3.11e+00 | 0.1055 |
7832 | BTG2 | P28T-E | Human | Esophagus | ESCC | 2.76e-74 | 2.86e+00 | 0.1149 |
7832 | BTG2 | P30T-E | Human | Esophagus | ESCC | 2.52e-37 | 3.40e+00 | 0.137 |
7832 | BTG2 | P31T-E | Human | Esophagus | ESCC | 1.10e-54 | 2.05e+00 | 0.1251 |
7832 | BTG2 | P36T-E | Human | Esophagus | ESCC | 1.28e-23 | 2.49e+00 | 0.1187 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:19033118 | Breast | Precancer | regulation of mRNA metabolic process | 38/1080 | 288/18723 | 1.63e-06 | 5.97e-05 | 38 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:00064028 | Breast | Precancer | mRNA catabolic process | 31/1080 | 232/18723 | 1.12e-05 | 2.93e-04 | 31 |
GO:00064018 | Breast | Precancer | RNA catabolic process | 34/1080 | 278/18723 | 2.88e-05 | 6.39e-04 | 34 |
GO:00346558 | Breast | Precancer | nucleobase-containing compound catabolic process | 42/1080 | 407/18723 | 1.91e-04 | 3.06e-03 | 42 |
GO:00098969 | Breast | Precancer | positive regulation of catabolic process | 48/1080 | 492/18723 | 2.62e-04 | 3.84e-03 | 48 |
GO:00313319 | Breast | Precancer | positive regulation of cellular catabolic process | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
GO:00467007 | Breast | Precancer | heterocycle catabolic process | 44/1080 | 445/18723 | 3.49e-04 | 4.88e-03 | 44 |
GO:00442708 | Breast | Precancer | cellular nitrogen compound catabolic process | 44/1080 | 451/18723 | 4.64e-04 | 6.12e-03 | 44 |
GO:00602138 | Breast | Precancer | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 5/1080 | 13/18723 | 5.51e-04 | 7.05e-03 | 5 |
GO:00435243 | Breast | Precancer | negative regulation of neuron apoptotic process | 19/1080 | 145/18723 | 6.83e-04 | 8.34e-03 | 19 |
GO:00009566 | Breast | Precancer | nuclear-transcribed mRNA catabolic process | 16/1080 | 112/18723 | 6.87e-04 | 8.36e-03 | 16 |
GO:19012157 | Breast | Precancer | negative regulation of neuron death | 24/1080 | 208/18723 | 9.50e-04 | 1.07e-02 | 24 |
GO:00194397 | Breast | Precancer | aromatic compound catabolic process | 44/1080 | 467/18723 | 9.55e-04 | 1.07e-02 | 44 |
GO:00602118 | Breast | Precancer | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 5/1080 | 15/18723 | 1.17e-03 | 1.26e-02 | 5 |
GO:0035914 | Breast | Precancer | skeletal muscle cell differentiation | 11/1080 | 67/18723 | 1.47e-03 | 1.52e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030186 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301811 | Breast | Precancer | RNA degradation | 14/684 | 79/8465 | 3.97e-03 | 2.37e-02 | 1.81e-02 | 14 |
hsa0301821 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa0301831 | Breast | IDC | RNA degradation | 16/867 | 79/8465 | 5.65e-03 | 3.13e-02 | 2.34e-02 | 16 |
hsa030184 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa030185 | Breast | DCIS | RNA degradation | 16/846 | 79/8465 | 4.45e-03 | 2.46e-02 | 1.82e-02 | 16 |
hsa030187 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
hsa0301812 | Endometrium | EEC | RNA degradation | 20/1237 | 79/8465 | 8.36e-03 | 3.88e-02 | 2.89e-02 | 20 |
hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301861 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa0301871 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BTG2 | SNV | Missense_Mutation | rs752692832 | c.335N>A | p.Arg112His | p.R112H | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BTG2 | SNV | Missense_Mutation | novel | c.403C>A | p.Leu135Ile | p.L135I | P78543 | protein_coding | tolerated(1) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BTG2 | SNV | Missense_Mutation | novel | c.206N>A | p.Arg69His | p.R69H | P78543 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BTG2 | SNV | Missense_Mutation | novel | c.450N>T | p.Lys150Asn | p.K150N | P78543 | protein_coding | tolerated(0.05) | benign(0.082) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BTG2 | SNV | Missense_Mutation | rs752692832 | c.335G>A | p.Arg112His | p.R112H | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
BTG2 | SNV | Missense_Mutation | c.205N>G | p.Arg69Gly | p.R69G | P78543 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
BTG2 | SNV | Missense_Mutation | c.196C>G | p.Arg66Gly | p.R66G | P78543 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-86-6562-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD | |
BTG2 | SNV | Missense_Mutation | rs757308128 | c.337N>T | p.Ile113Phe | p.I113F | P78543 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-MP-A4TK-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
BTG2 | SNV | Missense_Mutation | novel | c.310N>A | p.Val104Met | p.V104M | P78543 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CN-4730-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BTG2 | insertion | Frame_Shift_Ins | novel | c.18_19insCA | p.Thr7GlnfsTer19 | p.T7Qfs*19 | P78543 | protein_coding | TCGA-BA-6873-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |